Interview 24 Jan 2023 Watch: Queen’s University tackling antimicrobial resistance One of the biggest global challenges facing healthcare systems is bacteria and viruses becoming resistant to drugs. Antimicrobial resistance (AMR) contributes to the deaths of around 700,000 people annually. Without new drugs or ways of dealing with AMR, the number of deaths could reach as many as 10 million per year by 2050 and cause […] January 24, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 23 Jan 2023 Watch: pHion Therapeutics talks about next-generation mRNA vaccines pHion Therapeutics is a U.K.-based vaccine development company. It is developing a pipeline of therapeutic and prophylactic vaccines focussed on viral infections and oncology. The company’s proprietary RALA platform can deliver anionic molecules, such as mRNA and DNA, in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response. The RALA peptide-based […] January 23, 2023 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jan 2023 Cloned maggot enzyme wound treatment moves closer to reality Cambridge U.K. biotech company SolasCure, which is developing a wound cleaning technology, has published its pre-clinical results with the International Wound Journal, showing preliminary evidence that supports its new enzymatic debridement product for use in chronic wounds. Debridement, the removal of all infected and nonviable tissue, is a crucial prerequisite for a wound to heal. […] January 19, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2023 Multus Biotechnology closes $9.5M funding to bring cultivated meat closer to price parity Multus Biotechnology Limited, a U.K.-based start-up creating ingredients for the affordable scale-up of cellular agriculture, has completed a £7.9 million ($9.5 million) funding round led by Mandi Ventures. Other investors include SOSV, Big Idea Ventures and SynBioVen, alongside Asahi Kasei, a global company that contributes to a sustainable society by tackling evolving challenges in materials, […] January 17, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2023 TTP spinout Cellular Origins to focus on cell and gene therapies TTP plc, a technology and product development company, has announced the launch of Cellular Origins. Cellular Origins is a TTP spin-out, created to enable scalable, cost-effective and efficient manufacture of cell and gene therapies. Cellular Origins’ proprietary technology addresses the current barriers associated with the manufacture of advanced therapies that are in late-stage development, enabling […] January 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2023 Collaboration to boost pandemic preparedness, structure-based drug discovery and vaccine design A new Memorandum of Understanding (MoU) to facilitate collaboration in the field of pandemic preparedness and to promote further cooperation between the University of Oxford and Diamond Light Source has been announced. The University of Oxford and Diamond Light Source already have many links but now intend to develop their collaborative work to address multiple […] January 12, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2023 BioNTech partnering with UK Government on personalized mRNA cancer immunotherapies BioNTech SE has signed a memorandum of understanding (MoU) with the Government of the United Kingdom. The deal is set to benefit patients by speeding up clinical trials for personalized mRNA immunotherapies. The aim is to provide personalized cancer therapies for up to 10,000 patients by the end of 2030, either through clinical trials or […] January 6, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2023 Cancer Research UK and Turbine to partner on program Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK, has announced that it is partnering with Turbine AI, a tech-enabled biotech leveraging its proprietary Simulated Cell platform to solve complex diseases. The partnership will utilize Turbine AI’s platform to identify target patient populations […] January 5, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2023 Actimed Therapeutics raises £10M for cancer cachexia treatment Actimed Therapeutics Ltd has completed its second and final £5 million ($6 million) tranche of seed financing. The round was closed with an investment by Indian pharmaceutical company, Mankind Pharma, marking Mankind’s first overseas investment of this type. Actimed Therapeutics is a U.K. based clinical stage specialty pharmaceutical company focused on bringing innovation to the […] January 4, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jan 2023 Watch: Roquefort Therapeutics at BioFIT Roquefort Therapeutics is a biotech company developing first-in-class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth […] January 1, 2023 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Stem cell plasters could revolutionize heart surgeries Researchers at the University of Bristol in the U.K. funded by the British Heart Foundation (BHF) have developed ‘stem cell plasters’ to revolutionize the way surgeons treat children living with congenital heart disease, so they don’t need as many open-heart operations. Heart defects are the most common type of anomaly that develop before a baby […] December 21, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Startup Scout 19 Dec 2022 Green Bioactives grows medicines in plant cells Though plants may hold the key to new, effective medicines, sourcing these compounds sustainably is difficult. Green Bioactives devises eco-friendly ways to produce plant-derived drugs via plant cell cultures. For decades, the pharmaceutical industry has designed synthetic small molecule drugs and manufactured them via chemical synthesis. While this approach provides an easy way to supply […] December 19, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email